136 related articles for article (PubMed ID: 21539844)
1. Is Raf1 a nexus for cardiac hypertrophic signaling in human disease?
Del Re DP; Sadoshima J
J Mol Cell Cardiol; 2011 Jul; 51(1):1-3. PubMed ID: 21539844
[No Abstract] [Full Text] [Related]
2. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
[TBL] [Abstract][Full Text] [Related]
4. [New findings in Noonan syndrome and Leopard syndrome: activating mutations in RAF-1 and SOS-1].
Dereure O
Ann Dermatol Venereol; 2008; 135(8-9):624-5. PubMed ID: 18789305
[No Abstract] [Full Text] [Related]
5. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
[TBL] [Abstract][Full Text] [Related]
6. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
[TBL] [Abstract][Full Text] [Related]
7. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
8. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
[TBL] [Abstract][Full Text] [Related]
9. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.
Levin MD; Saitta SC; Gripp KW; Wenger TL; Ganesh J; Kalish JM; Epstein MR; Smith R; Czosek RJ; Ware SM; Goldenberg P; Myers A; Chatfield KC; Gillespie MJ; Zackai EH; Lin AE
Am J Med Genet A; 2018 Aug; 176(8):1711-1722. PubMed ID: 30055033
[TBL] [Abstract][Full Text] [Related]
10. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
12. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
[TBL] [Abstract][Full Text] [Related]
13. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
[TBL] [Abstract][Full Text] [Related]
14. Lessons From a Genotype-Phenotype Study About the Clinical Spectrum of Hypertrophic Cardiomyopathy Associated With Noonan Syndrome With Multiple Lentigines and PTPN11-Mutations.
Östman-Smith I
Circ Genom Precis Med; 2023 Aug; 16(4):359-362. PubMed ID: 37325916
[No Abstract] [Full Text] [Related]
15. Noonan syndrome and clinically related disorders.
Tartaglia M; Gelb BD; Zenker M
Best Pract Res Clin Endocrinol Metab; 2011 Feb; 25(1):161-79. PubMed ID: 21396583
[TBL] [Abstract][Full Text] [Related]
16. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
[TBL] [Abstract][Full Text] [Related]
17. RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.
Gelb BD; Tartaglia M
J Clin Invest; 2011 Mar; 121(3):844-7. PubMed ID: 21339640
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
[TBL] [Abstract][Full Text] [Related]
19. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
[TBL] [Abstract][Full Text] [Related]
20. PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype".
Digilio MC; Sarkozy A; Pacileo G; Limongelli G; Marino B; Dallapiccola B
Eur J Pediatr; 2006 Nov; 165(11):803-5. PubMed ID: 16733669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
